Elizabeth Begier

Pfizer (United States) — United States

Medicine · Health Sciences

32h-index4.3kcitations236works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Respiratory viral infections research(108), Pneumonia and Respiratory Infections(55), HIV/AIDS Research and Interventions(26), HIV, Drug Use, Sexual Risk(22), Viral gastroenteritis research and epidemiology(18)

Publications232 total

Methodological Issues in Taquet et al.‘s analysis preclude any conclusions regarding AS01 adjuvant’s specific role in dementia prevention
npj Vaccines·2025Open Access
Estimation of General Practitioner Visits, Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus and Influenza Virus, and Costs Associated With Hospitalizations, in Older Adults in France From 2010 to 2020
Open Forum Infectious Diseases·2025Open Access
Sensitivity of RSV detection by PCR in respiratory samples is not reduced by a 24 h delay from sampling to testing with storage at room temperature
Molecular Medicine·2025Open Access
Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis
Clinical Infectious Diseases·2025Open Access
Intensive Care Unit Stay and Mechanical Ventilation Among Adults with Respiratory Syncytial Virus-Related Hospitalization by Age and Comorbidity Status
Infectious Diseases and Therapy·2025Open Access
Effectiveness of the 13-valent pneumococcal vaccine against hospitalized community-acquired pneumonia among adults ≥60 years in Madrid-Spain after the COVID-19 pandemic
Vaccine X·2025Open Access
Validating the ROME COPD exacerbation classification in a hospitalised cohort
2025
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
Clinical Infectious Diseases·2025· 2 citedOpen Access
Effect of RSV Vaccine on Heart Failure Hospitalizations
Journal of the American College of Cardiology·2025· 2 citedOpen Access
RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults
New England Journal of Medicine·2025· 12 cited
Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults
JAMA·2025· 11 citedOpen Access
Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial
European Heart Journal·2025· 3 citedOpen Access
Characteristics of In- and Off-season Respiratory Syncytial Virus Episodes—United States, 2016–2020
Open Forum Infectious Diseases·2025Open Access
Estimated Incidence of Hospitalisations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Norway between 2010 and 2019: A Time-Series Modelling Study
Journal of Epidemiology and Global Health·2025· 1 citedOpen Access
A pragmatic individually randomized trial to evaluate bivalent RSV prefusion F protein–based vaccine effectiveness for preventing RSV hospitalizations in adults aged 60 years or above (DAN-RSV): Rationale and trial design
American Heart Journal·2025· 2 citedOpen Access
Acute coronary syndrome after an infective exacerbation of chronic obstructive pulmonary disease. A prospective cohort study of acute lower respiratory tract disease in hospitalised adults
ERJ Open Research·2025Open Access
Viral Etiologies of Acute Respiratory Illness in Older Adults and of Congestive Heart Failure and Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization During 2 Prepandemic Respiratory Seasons
Open Forum Infectious Diseases·2025Open Access
Respiratory syncytial virus-attributable hospitalizations among adults in high- and middle-income countries: application of the Global Burden of Disease framework
EClinicalMedicine·2025· 8 citedOpen Access
Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study
Journal of Antimicrobial Chemotherapy·2025· 4 citedOpen Access
Can We Compare Attributable Risk of Adverse Events with the Self-Controlled Case Series Design in Vaccine Safety Studies? A Use Case of Guillain-Barré Syndrome
2025Open Access
page 1 of 12Next →

Frequent Co-authors

Bradford D. Gessner(13), Alejandra Gurtman(6), Annaliesa S. Anderson(5), Kent A. Sepkowitz(4), Luis Jódar(4), Daniel Curcio(4), Mark H. Rozenbaum(4), David Cooper(4), James L. Hadler(3), Catherine Hyams(3), Robin Marlow(3), Anna Morley(3), Jennifer Oliver(3), Sharon Gray(3), Adam Finn(3), James Campling(3), María García González(3), Warren V. Kalina(3), Jessica E. Atwell(3), Harish Nair(3)